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Abstract
Hepatorenal syndrome is a complication of end stage liver disease. It is a unique form of 
functional renal failure related to kidney vasoconstriction in the absence of underlying kidney 
pathology. Hepatorenal syndrome is classified into 2 types: type-1 HRS shows a rapid and 
progressive decline in renal function with a very poor prognosis (median survival of about 
2 weeks); type-2 HRS has a more stable kidney failure, with a median survival of 6 months; 
its main clinical manifestation is refractory ascites. The most appropriate therapy for HRS 
is liver transplantation but only a minority of HRS patients undergo the procedure due to 
the high mortality; survival among liver transplant recipients is lower in HRS than among 
their counterparts without HRS. A large body of evidence, based on observational studies 
and randomized controlled trials, has been accumulated in the last decade showing that 
terlipressin represents a milestone in the management of HRS. According to our meta-
analysis of randomized trials comparing terlipressin vs. placebo (five trials, n=243 patients), 
the pooled rate of patients who reversed HRS by terlipressin was 8.09 (95% CI, 3.52; 18.59) 
(P<0.001). Among vasoconstrictors, terlipressin (a V1 vasopressin agonist) is the most widely 
used; however, noradrenaline is another good choice. Vasoconstrictor drugs alone or with 
albumin reduce mortality compared with no intervention or albumin (RR of mortality, 0.82; 
95% Confidence Intervals, 0.70; 0.96) (P<0.01). Two series of patients with HRS recurrence after 
the first treatment have recently shown that long-term therapy with terlipressin and albumin 
is beneficial as a bridge to liver transplant. Nevertheless, recovery of renal function can be 
achieved in less than 50% of patients with HRS after terlipressin use and the recovery of renal 
function may also be partial in patients who are defined full responders. Renal replacement 
therapy should not be considered a first-line therapy for HRS Clinical trials are under way in 
order to assess efficacy and safety of novel therapeutic agents for the treatment of type-1 and 
type-2 HRS.
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Historical perspectiveThe association between liver disease and renal failure had been known for more than 
a hundred years. Frerichs was the first investigator who reported on the occurrence of 
oliguria in patients with ascites since 1877 [1]. The term ‘hepatorenal syndrome’ was used 
in 1939 to describe the occurrence of renal failure after biliary surgery in patients showing 
a pathological pattern of acute tubular necrosis or tubular interstitial nephritis [2-3]. 
Later on, the term ‘hepatorenal syndrome’ was used to report on any kind of simultaneous 
impairment of liver and kidney function. The presence of low sodium excretion in the urine 
of patients with HRS was discovered by Hecker and Sherlock in 1956 [4]. The functional 
nature of this renal failure was emphasized by Koppel et al. [5] who proved in the 1960s 
that kidneys obtained from patients who dead with HRS could be transplanted in patients 
with renal failure of different aetiology, since these kidneys could recover their function 
after transplant. The first consensus definition on the optimal criteria to define HRS was 
agreed upon at the 1994 meeting of the International Ascites Club [6] but new criteria were 
developed by the IAC with a meeting held in San Francisco in 2006 [7]. 
Epidemiology and clinical manifestations of HRS
HRS is a potentially reversible form of renal failure that occurs in patients with cirrhosis 
and ascites as well as in patients with acute liver failure. In cirrhotic patients with ascites, 
the most common causes of acute renal failure are: pre-renal (around 37%), acute tubular 
necrosis (around 42%), and post-renal failure (0.3%); HRS is around 20% [8-9]. The 
cumulative probability of HRS in patients with cirrhosis and ascites is equal to 18% after 1 
year, rising to 39% at 5 years [10]. 
Predictors for the development of HRS have been suggested to include liver size, serum 
sodium concentration (<133 mEq/L), increased plasma renin activity (>3.5 ng/mL/h), 
and increased resistive index of renal arcuate and interlobar arteries (>0.7 by Doppler 
ultrasound). Some investigators noted the role of total bilirubin and prothrombin time 
(major determinants of the Child-Pugh score) as significant and independent predictors of 
HRS [11-12].   
HRS type 1 is an acute disease often induced by precipitating factors such as bacterial 
infections (57%), gastrointestinal hemorrhage (36%), and large volume paracentesis without 
plasma expansion (7%) [11-12]. Spontaneous bacterial peritonitis represents the most 
important bacterial infection associated with HRS occurrence and it occurs in many patients 
despite a rapid resolution of the infection with non-nephrotoxic antibiotics. Renal failure can 
be precipitated in cirrhotic patients with ascites by all types of bacterial infections; in most cases renal failure is transient and recovers after the resolution of the infection but, in some 
cases, an acute renal failure with the hallmarks of type-1 HRS can occur. HRS commonly 
develops in patients with advanced cirrhosis; thus, HRS patients have jaundice and other 
stigmata of chronic liver disease such as spider nevi, palmar erythema, and finger clubbing. 
Further clinical manifestations include splenomegaly, ascites, hepatic encephalopathy, and 
bleeding. The urine output is reduced particularly in type-1 HRS, and low arterial blood 
pressure usually occurs. In patients with type-1 HRS the main clinical presentation is overt 
acute renal failure whereas the degree of the impairment of renal failure is less severe and 
more stable over time in type-2 HRS patients. 
In contrast, HRS type 2 is not precipitated by acute events and is characterized by a 
progressive deterioration of renal function related to the degree of portal hypertension. 
Type-2 HRS develops spontaneously in many patients with cirrhosis and ascites and 
represents the real functional renal failure associated with cirrhosis. Patients with type-2 
HRS are predisposed to develop type-1 HRS following infections or other trigger events. The 
patho-physiological differences between type-1 and type-2 HRS are not fully elucidated and 
this is a point of intense research [11-12]. 
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Pathogenesis of HRS
The pathogenesis of HRS is not completely understood but various hypotheses linking 
the alterations of renal haemodynamics and ascites formation have been made [13-14]. The 
most popular hypothesis is the ‘arteral vasodilation hypothesis’, proposed by Schrier et al. in 
1988 [15], the development of HRS is associated with the circulatory changes seen in cirrhosis 
with portal hypertension, including splanchnic arterial vasodilation. Splanchnic vasodilation 
may result in effective arterial underfilling and is clinically manifested by arterial hypotension. 
In the early stage of cirrhosis, the increase in heart rate and cardiac output compensates the 
reduction of the effective blood volume; as the liver disease progresses leading to a further 
impairment in portal hypertension and hepatic insufficiency, there is activation of the 
systemic endogenous vasoconstrictor systems (the sympathetic nervous system, the renin- 
angiotensin- aldosterone system, and the non-osmotic release of vasopressin). The activation 
of these systems explains some functional abnormalities at kidney level such as renal sodium 
retention leading to ascites, and renal water retention leading to hyponatremia. Thus, 
vasoconstriction in several vascular regions (including liver and brain) occurs. In the early 
stage of cirrhosis, an increased activity of systemic and renal vasodilators preserves renal 
perfusion despite activation of RAAS and SNS. The most important renal vasodilators being 
kinins, nitric oxide, prostaglandins, and natriuretic peptides. In the late stage of cirrhosis, 
renal perfusion cannot be maintained because of extreme arterial underfilling causing lower 
activity of local vasodilators and maximal activation of vasoconstrictors; at this critical point 
HRS occurs [15]. 
The most recent advances in the pathogenesis of HRS have given emphasis on the notion 
that the cardiac output is unable to prevent a severe reduction of effective circulating volume 
due to the splanchnic arterial vasodilation. Cardiac output may be low, high or normal, but 
is relatively insufficient to prevent a severe reduction of effective circulating volume due to 
splanchnic arterial vasodilation in patients having HRS. It is still unclear why cardiac output 
worsens in end-stage liver disease but the so-called ‘cirrhotic cardiomyopathy’ has been 
recently recognized [16]. Cardiac dysfunction reverses 9 to 12 months after LT suggesting that 
the diseased liver rather than the cause of liver disease is responsible for cardiac dysfunction. 
Specific cardiac abnormalities have been recognized to describe ‘cirrhotic cardiomiopathy’, 
including reduced systolic and diastolic responses to stress stimuli, enlargement of cardiac 
chambers, electrophysiological repolarisation abnormalities. In addition, other factors such 
as inflammatory cytokines, nitric oxide, carbon monoxide and other substances evoked by 
the reaction to bacterial infection have been implicated in the pathogenesis of  impaired 
cardiac function in patients with end-stage liver disease. 
Overall, HRS is featured by a marked renal vasoconstriction with a consequent reduction 
in renal plasma flow and glomerular filtration rate, absence of pathological changes in the 
kidney tissue and intact activity of renal tubules. Splanchnic arterial vasodilation is thought 
to be related to an increased activity of endogenous vasodilators due to portal hypertension 
and/or hepatic failure (including nitric oxide, glucagon, prostacyclin, and endogenous 
opiates). The relative role of each of them is unclear and probably varies over the different 
stages of the liver disease (Figure 1).    
Diagnosis of HRS
There are no specific diagnostic tests to distinguish between HRS and other causes of 
renal failure that may occur in cirrhosis, and the criteria for diagnosing HRS have recently 
been reviewed by the IAC [7] (Table 1). The most important changes in the revised criteria are 
as follows: the minor diagnostic criteria are no longer considered essential for the diagnosis 
of HRS; the ongoing bacterial infections are not an exclusion criteria for the diagnosis of 
HRS; creatinine clearance is no more considered as a tool for the diagnosis since it offers 
few advantages in terms of accuracy in the estimation of renal function as compared to the 
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use of serum creatinine. Although various causes of kidney failure in the setting of advanced 
liver disease exist such as volume depletion, shock (haemorragic or septic shock), exposure 
to nephrotoxic drugs, or parenchimal renal failure (i.e., glomerulonephritis), renal failure 
in cirrhosis most commonly occurs in the absence of these factors. Some weakness in the 
criteria set by the IAC for the diagnosis of HRS may probably exist; as an example, patients 
with cirrhosis frequently experience acute ischemic tubular necrosis due to slight decreases 
in arterial pressure (without shock) at various times. A higher susceptibility to ischemia due 
to renal vascular abnormalities has been noted in cirrhotic patients [17].    
HRS is a life-threatening complication of cirrhosis and is classified into 2 types based 
on the clinical course: type-1 HRS shows a rapid and progressive decline in renal function as 
measured by a doubling of the baseline serum creatinine to a level greater than 2.5 mg/dL, 
or a 50% decline in the baseline creatinine clearance to a level less than 20 mL/min in less 
than 2 weeks. Type-2 HRS patients have an impairment in the renal function as measured by 
a serum creatinine greater than 1.5 mg/dL but not meeting the criteria for the type-1 HRS. 
Type-2 HRS is a more chronic form and has a corresponding better prognosis. The most 
important clinical consequence of type-2 HRS is ascites with poor or no response to diuretics 
(a condition known as refractory ascites). The median survival of a patient with type-1 or 
Fig. 1.
Table 1. 
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type-2 HRS is about 2 weeks and 4-6 months, respectively. These survival rates are lower 
than that observed in patients with ascites and intact kidney function. Spontaneous recovery 
from HRS is rare unless there is an improvement in liver function.  
Outcome of patients with HRS and LT
The best treatment for HRS is liver transplantation but many patients die before LT 
because of the short survival associated with HRS, and organ shortage. HRS should be treated 
before LT in an attempt to improve the renal function as evidence has shown that patients 
with HRS who receive transplants have more complications and moderately higher mortality 
rate than those without HRS. Patients with HRS before liver transplant are more likely to be 
ICU bound (HRS vs. non-HRS; 90% vs. 33.4%; P<0.001) and require dialysis (32.2% versus 
1.5%; P<0.001) than their counterparts without HRS [18-19]. HRS patients have severely 
reduced GFR (HRS vs. non-HRS, 19.9 vs. 97.1 mL/min; P<0.001) and have higher serum levels 
of bilirubin (17.2 mg/dL vs. 9.37 mg/dL; P=0.007) [18-19]. Postoperatively, these patients 
spend more days in the ICU (HRS vs. non-HRS, 20.8 vs. 4.4; P=0.001) and have a higher 
postoperative dialysis (57.9 vs. 11.1%; P=0.001) requirement [17-18]. Approximately 10% 
of patients with HRS will progress to ESRD during the post-operative period as compared 
with 0.8% of recipients without HRS [18-19].
Ruiz et al. [20] at the Baylor Regional Liver Transplant Institute identified 130 patients 
with HRS undergoing LT over a 10-year period  (since January 1995 to December 2004) with 
an overall incidence of 9%. A total of 13 patients developed type-1 HRS and 117 patients 
evolved with type-2 HRS. In the whole group, patient survival rates at 1, 3, and 5 years were 
74%, and 68%, and 62%, respectively. Survival was significantly worse when compared 
to non-HRS patients undergoing LT over the same study period (P=0.0001). According to 
Distant and Gonwa, 4-year survival among LT recipients was 70% vs. 60% in non-HRS and 
HRS patient groups, respectively [18].   
Despite the disappearance of the hemodynamic and neuro-humoral abnormalities by 1 
month after LT, glomerular filtration improves only partially, reaching 30-40 mL/min by 1-2 
months [21]. Because tacrolimus or cyclosporine may contribute to this impairment of renal 
function, it has been suggested to delay the administration of these drugs until a recovery of 
renal function is noted, usually 48-72 hours after liver transplantation. 
Pharmacologic treatment of HRS   
Up to 1999, the prognosis of cirrhotic patients developing HRS was very poor with a 
mortality rate reaching 100% in some reports, and a median survival time of two weeks 
from diagnosis. Evidence has been accumulated showing that systemic vasoconstrictors for 
the treatment of type-1 or -2 HRS have really changed the outcome of these patients [22-
24]. Systemic vasoconstrictors used for HRS include vasopressin analogues (ornipressin) 
[25-27], somatostatin analogues (octreotide) [28-31], alpha-adrenergic agonists including 
midodrine [32] and noradrenaline [33-38]. Medical literature is abundant on clinical studies 
regarding terlipressin, a vasopressin analogue, for the treatment of HRS [39-56]. In many 
studies, vasoconstrictors were given in combination with albumin, which probably improves 
their efficacy [57]. Terlipressin had been licensed first for the management of acute variceal 
bleeding and has a much greater effect on vascular (V1) than on renal vasopressin receptors 
(V2). Abundant V1 receptors are present in the splanchnic vasculature causing greater vasoconstriction in the mesenteric circulation than in renal or other vascular systems. The 
rationale for the administration of terlipressin is to counteract the extreme splanchnic arterial 
vasodilation in patients with HRS resulting in an improvement of circulatory function (i.e., 
increase in the effective arterial blood volume), which leads to a suppression of the activity 
of the vasoconstrictor systems (i.e., renin-angiotensin and sympathetic nervous system) 
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and subsequent increase of renal perfusion and glomerular filtration rate. Terlipressin has 
been used either as an intravenous bolus starting at an initial dose of 0.5 mg every 4-6 h 
or continuous intravenous infusion starting at an initial dose of 2 mg/day. In patients with 
no significant reduction of serum creatinine within 3 days, the initial dose of terlipressin is 
doubled. The maximal doses of terlipressin used in the treatment of type-1 HRS are 2 mg 
every 4-6 hours by intravenous boluses, or 12 mg/day by continuous intravenous infusion, 
respectively.  
Rationale of HRS therapy 
Several studies from various transplant units have convincingly demonstrated that 
pre-transplant renal function is a major determinant of survival after liver transplantation 
[21,58].  Patients with HRS have a high mortality rate while awaiting transplantation; in 
addition, the presence of HRS at the time of LT is associated with a poor outcome after LT [18]. 
The presence of HRS also carries an increased risk of complications post-transplantation, 
including bleeding, and infections; a greater use of medical resources (longer hospitalizations 
and prolonged stays in intensive care units) has been calculated [18]. The impact of treatment 
of HRS before LT on outcome after transplantation has been evaluated by Restuccia et al. 
[59]. The outcome of patients with HRS (n=9) treated with vasopressin analogues before LT 
was compared with that of a contemporary control group of patients without HRS (n=27) 
matched by age, staging of liver disease, and immunosuppressive therapy. Three-year 
survival probability was not different between the two groups, 100% vs. 83%, P=0.15. No 
significant differences were found between the two groups with respect to the incidence of 
impairment of renal function after LT, 22% (2/9) vs. 30% (8/27) within the first 6 months 
after transplantation. Severe infections (22% vs. 33%), acute rejection (33% vs. 41%), and 
transfusion requirement (11+3 vs. 10+2 units) were not significantly different between the 
two groups. The duration of the stay in intensive care units as well as the total duration of the 
hospitalization were similar between the two groups (6+1 vs. 8+1 days, and 27+4 vs. 31+4, 
respectively) (P=NS for both) [59].  
Therapy of HRS: Vasoconstrictors (Observational studies) 
Many clinicians have started to use terlipressin in patients with HRS but the majority of 
these studies had small size and uncontrolled design [39-56]. We have previously evaluated 
efficacy and safety of terlipressin in the treatment of hepatorenal syndrome by a pooled 
analysis of observational (uncontrolled) studies [60]. The primary outcome (as a measure 
of efficacy) was the frequency of responder patients (i.e., patients who had reversal of HRS 
after terlipressin therapy). The secondary outcomes included the frequency of responders 
who had recurrence of HRS after terlipressin withdrawal. Complete reversal of HRS was 
defined by a decrease of serum creatinine with a final value <1.5 mg/dL. Ten clinical studies 
(n=154 unique patients) were enrolled. The pooled frequency of responder patients after 
terlipressin therapy was 0.52 (95% Confidence Intervals, 0.42; 0.61), according to a random-
effects model. An important drawback of terlipressin therapy is that hepatorenal syndrome 
recurrence after terlipressin withdrawal is very common, especially in type 2 hepatorenal 
syndrome [37]. A lower relapse rate (0-5%) has been reported after vasoconstrictor therapy 
in HRS type 1 [37]. In our analysis, the frequency of responder patients who showed 
recurrence of HRS after terlipressin withdrawal was 0.55 (95% CI, 0.40; 0.69) but evidence 
on this point was provided in six clinical studies only [60]
Responder patients with recurrence of HRS after terlipressin withdrawal should be 
treated again and this approach can be effective. Two series (n=6 patients overall) have 
been recently published on long-term treatment (terlipressin and albumin) of patients with 
recurring type-1 HRS who are listed with high priority [61-62]. Continuous therapy with 
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terlipressin and albumin was effective as a bridge to LT over a period of 2-8 months; no 
major side-effects were observed during terlipressin use. The outcome after LT was excellent 
in four patients as they did not develop chronic kidney disease or required renal replacement 
therapy after LT.    
Terlipressin use in clinical practice has been limited by several factors, i.e. it is expensive, 
is not available in many countries including the United States and can give ischemic side-
effects requiring interruption of treatment [63]. The summary estimate of the rate of 
patients showing side-effects and drop-outs during terlipressin therapy was 0.25 (95% 
CI, 0.18; 0.32) and 0%, according to our systematic review [60]. HRS patients are prone 
to develop complications as they show severe dysfunction in several organs in addition 
to liver and kidney. Terlipressin is probably safer than other vasoconstrictor agents (i.e., 
ornipressin) but adverse effects during terlipressin therapy had been already noted. Thus, 
a careful selection of patients and close clinical surveillance during terlipressin therapy are 
needed. Contraindications to terlipressin use include a history of coronary artery disease, 
cardiomyopathies, cardiac arrhythmias, cerebrovascular disease, chronic obstructive 
pulmonary disease, arterial hypertension, and obliterative arterial disease of the lower 
limbs. The tolerance to terlipressin therapy reported by some authors was probably related 
to the efforts made to exclude patients with contraindications to treatment.  
An important question is prediction of response to terlipressin treatment [22-24]. The 
most consistent predictor of response to terlipressin and of survival is the baseline serum 
creatinine, bilirubin, and an increase in mean arterial pressure of  >5 mmHg at day 3 of 
treatment. Patients who most likely will benefit from terlipressin have earlier onset renal 
failure (serum creatinine <3 mg/dL). It has been calculated that the cut-off level of serum 
bilirubin that best predicted response to treatment was 10 mg/dL. As reported below, 
an early increase in the hyperdynamic circulation  (measured by sustained rise in mean 
arterial pressure) is also important for reversal of HRS. These findings have implications for 
the management of HRS patients, as it is necessary to start treatment as early as possible. 
Predictive factors of response in various studies in patients with HRS included baseline 
Child-Pugh and MELD scores; interestingly, a Child-Pugh score above 13 is predictive of a 
lack of beneficial effect of terlipressin on renal function. Another independent predictive 
factor of improvement of renal function in response to terlipressin is younger age and the 
reasons for this appear unclear [49]. 
Therapy of HRS: Vasoconstrictors (RCTs) 
More convincing evidence on the efficacy and safety of terlipressin has been provided 
by some RCTs [40, 53, 56, 64-65]. Systematic reviews of the literature with meta-analyses of 
RCTs comparing terlipressin versus placebo on renal function and survival of patients with 
HRS have been recently reported [66-67]; we identified five studies (n=243 patients) in our 
meta-analysis [66]. We observed a significant increase in reversal of hepatorenal syndrome 
among study (terlipressin) versus placebo patients; the pooled OR of HRS reversal rate was 
8.09 (95% CI, 3.521; 18.59; P=0.0001) [66]. No impact of terlipressin use on survival was 
noted, pooled OR for survival rate 2.064; 95% CI, 0.939; 4.538 (P=0.07) [66].
In their systematic review of randomized trials on vasosoconstrictor drugs for HRS 
(n=376 patients) the Cochrane Hepato-Biliary Group found that vasoconstrictor drugs 
reduced mortality compared with no intervention at 15 days only (RR, 0.60; 95% Confidence 
Intervals, 0.37-0.97) [68]. The presence of a link between terlipressin therapy and survival 
over the short-term only may be explained by taking account that the prognosis in HRS 
population is largely dependent upon the degree of liver failure. A significant impairment 
of liver function is a poor predictor for the response to terlipressin but also for their overall 
survival [69].  
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Therapy of HRS: Arterial blood pressure and vasoconstrictors
 Although the purpose of vasoconstrictor therapy in HRS is to specifically optimize 
renal haemodynamics, this effect is typically achieved with a concomitant increase in 
systemic blood pressure. A pooled analysis of 21 clinical studies (n=501 patients) revealed 
that an increase in mean arterial pressure is strongly associated with a decline in serum 
creatinine (rho=-0.76, P<0.001) [70]. On average, for every 1-mmHg increase in MAP, a 0.12 
mg/dL decline in serum creatinine is expected; every 8.6 mmHg increase in MAP is associated 
with a 1.0 mg/dL decline in serum creatinine. The authors suggested that, independent 
of which vasoconstrictor is chosen, targeting a systematic rise in MAP of around 10-15 
mmHg during vasoconstrictor therapy may lead to more favourable kidney outcomes. Most 
studies included in this review tested terlipressin as vasoconstrictor; two papers addressed 
norepinephrine. Physicians have been so far reluctant to adopt norepinephrine due to 
the fear of aggravating renal hypoperfusion, norepinephrine induces afferent arteriolar 
vasoconstriction through α1 adrenergic receptor stimulation. Some small-sized RCTs have 
recently reported that noradrenaline may be a good alternative to terlipressin in improving 
renal function [35-38] (Table 2). Our preliminary meta-analysis of some RCTs (n=108 
unique patients) showed that the pooled Odds Ratio of HRS reversal after vasoconstrictor 
therapy was 0.96 (95% CI, 0.45; 2.07, NS), as listed in the Galbraith plot (Figure 2). In other 
words, noradrenaline and terlipressin were equally effective in the treatment of HRS. All 
these studies calculated that noradrenaline was less expensive than terlipressin. It has been 
speculated that norepinephrine increases the mean arterial pressure by its α
1
 –mediated 
effect on systemic vascular resistance and its β
1
-mediated inotropic activity; these activities 
overcoming its local effects on renal circulation.
Therapy of HRS: TIPS 
In addition to vasoconstrictor therapy, an alternative approach includes TIPS. TIPS is a 
non-surgical procedure of portal decompression used as an alternative therapy for cirrhotic 
patients bleeding from oesophageal or gastric varices who do not respond to endoscopic 
and medical treatment. An interventional radiologist will place a side-to-side portocaval 
shunt that links the portal and hepatic veins within the hepatic parenchyma. TIPS reduces 
portal pressure and the filtration in the peritoneal space to a level which can be drained by 
the lymphatic system. TIPS returns some of the volume of blood pooled in the splanchnic circulation to the systemic circulation. 
Within four weeks after TIPS urinary sodium excretion and serum creatinine improve 
and, in combination with diuretics, can normalise within 6-12 months. This occurs in 
Table 2. Baseline characteristics of RCTs (Terlipressin versus Noradrenaline)
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[72]. The role of TIPS in the treatment of HRS has been addressed in a few papers [73-76]; Guevara et al. were the first authors to treat HRS patients by TIPS; renal function strongly 
improved in 6 of the 7 patients with type-1 HRS [73]. Brensing et al. treated 31 HRS patients (14 
type 1 and 17 type 2), 77% (24/31) exhibited sustained improvement in GFR. Cox regression 
analysis showed that bilirubin (P<0.001) and HRS type (P<0.05) were independent survival 
predictors after TIPS [74]. In a recent series of type-1 HRS patients, Testino et al treated with 
TIPS nine consecutive patients having severe acute alcoholic hepatitis, 30 days after TIPS 
insertion serum creatinine was 1.6+0.6 vs. 5.2+0.9 at baseline (P<0.04) [76]. 
However, there are some drawbacks associated with TIPS including trans-capsular 
puncture, and shunt stenosis. Patients with advanced cirrhosis are not good candidates to TIPS 
procedure as they are at risk for worsening liver failure and/or hepatic encephalopathy. TIPS 
activity appears to be slow and beneficial in some patients only. Many clinical, biochemical 
and neuro-humoral parameters improve but do not fully reverse after TIPS insertion.   
Therapy of HRS: Dialysis
Initiation of RRT is controversial in patients with type 1 HRS who are not candidates 
for liver transplantation due to poor life expectancy and high morbidity /mortality rates 
associated with RRT. Early studies demonstrated that initiation of RRT in cirrhotic patients 
is associated with increased mortality due in part to the increased risk of haemorrhage 
and hypotension [77]. As reported by Keller et al. [78], HRS patients who underwent RRT 
survived more than those who did not receive RRT but 33% of the days gained were spent 
in the hospital. 
For HRS patients who are non-responder to vasoconstrictors or TIPS and are waiting 
for a liver transplant or are being evaluated for OLT, RRT should be considered a good choice 
[77]. The decision between intermittent haemodialysis or continuous renal replacement 
therapy should be individualized as evidence currently shows that neither has been shown 
to be superior to the other, even if CRRT is probably better tolerated in unstable patients 
[79-82].
Newer approaches are currently under evaluation for HRS patients including the 
extracorporeal albumin dialysis (MARS) or the Prometheus system. MARS (molecular 
adsorbent recirculation system) is designed to make clearance of albumin-bound toxins 
(i.e., bile acids) and water-soluble cytokines (i.e., IL-6) which have been implicated in 
the HRS pathogenesis. In a randomized study, Mitzner et al. [83] showed that MARS was 
Fig. 2.association with increases in 
urinary volume, glomerular 
filtration rate, and serum sodium concentration. The activity of vasoconstrictor and 
anti-natriuretic systems such 
as RAAS, SNS, and arginine 
vasopressin (AVP) is lowered and an amelioration of renal circulation occurs. 
The effect of TIPS on renal function and haemodynamics 
has been investigated in 
various studies on patients with cirrhosis and refractory 
ascites [71]. TIPS have been 
proved to be effective even in 
patients with cirrhosis and 
parenchymal renal disease 
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superior to CRRT in type 1 HRS patients in terms of patient survival, improved clinical and 
biochemical parameters were also found. A more recent study demonstrated that MARS 
was ineffective in improving systemic haemodynamics in six patients with type 1 HRS who 
failed vasoconstrictor treatment; only transient reduction in serum creatinine occurred 
[84]. Another study on 32 HRS-1 patients reported a rate of complete renal response of 
28% (9/32) [85]. Prometheus employs fractional plasma separation, and adsorption with 
haemodialysis could be utilized to treat liver failure patients who have a need for RRT. It 
has not yet been studied in HRS population and has been used in hepatic failure. MARS 
and Prometheus may work as a bridge to OLT but they should be considered experimental 
approaches until controlled studies will be done. 
Conclusions
Hepatorenal syndrome remains frequent among patients with end stage liver disease. 
The main clinical manifestations include renal failure (with low urine output) and sodium 
and water retention (with ascites, edema and dilutional hyponatremia). Occurrence of HRS 
is associated with a lower survival before and after LT, compared to non-HRS patients. Liver 
transplantation is the preferred treatment for HRS. Terlipressin is a vasopressin analogue 
which improves renal perfusion by inducing vasoconstriction of the splanchnic circulation. 
Convincing evidence has been given over the recent years showing that the combined therapy 
(terlipressin with albumin) has really improved the prognosis of HRS patients. Continuous 
treatment with terlipressin until liver transplantation in patients with HRS recurrence after 
the first treatment is a good option as a bridge to liver transplantation. Combination therapy 
(terlipressin plus albumin) should be improved with the aim to reduce the rate of non-
responder or relapser patients. RRT should be offered as a bridge to patients awaiting liver 
transplant or those undergoing liver transplant evaluation.
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